Diagnosis of Subtype 2B von Willebrand Disease in a Patient with 2A Phenotype of Plasma von Willebrand Factor

Summary

Type 2A of von Willebrand disease refers to qualitative variants with decreased platelet dependent function that is associated with the absence of high molecular weight forms of von Willebrand factor (vWF) multimers. Type 2B refers to qualitative variants with increased affinity for platelet glycoprotein lb. In this report we describe the study of a patient who has been previously diagnosed as having subtype 2A von Willebrand disease (vWD), because she had no heightened ristocetin-induced platelet aggregation, no large and intermediate molecular weight von Willebrand factor (vWF) multimers in plasma, and no increase in plasma vWF capacity to bind to normal platelets in the presence of low ristocetin concentrations. The DNA sequencing of the 3’ part of the exon 28 of the vWF gene where most of the subtype 2A mutations have already been identified, did not detect any nucleotide change. At variance, a G to A transition changing the encoded amino acid residue from Val 553 to Met in mature vWF, was found in the 5’ part of this exon. This mutation which has already been found in several unrelated families with 2B vWD and the increased binding of the patient platelet vWF on normal platelets in the presence of low ristocetin concentrations provide evidence for subtype 2B vWD. This study thus illustrates the importance of the molecular characterization of patients in the correct diagnosis and classification of type 2 vWD.

• References

• 1 Ruggeri ZM, Zimmerman TS. Von Willebrand factor and von Willebrand disease. Blood 1987; 70: 895-904
• 2 Ruggeri ZM, Zimmerman TS. Classification of von Willebrand disease. J Clin Lab Anal 1987; 1: 353-362
• 3 Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 7: 520-525
• 4 Ruggeri ZM, Pareti FI, Mannucci PM, Ciavarella N, Zimmerman TS. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand’s disease. New Engl J Med 1980; 302: 1047-1051
• 5 Ruggeri ZM, Zimmerman TS. Variant von Willebrand’s disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest 1980; 65: 1318-1325
• 6 Weiss HJ, Pietu G, Rabinowitz R, Girina J-P, Rogers J, Meyer D. Heterogeneous abnormalities in the multimeric structure, antigenic properties, and plasma-platelet content of factor VIII/von Willebrand factor in subtypes of classic (type I) and variant (type IIA) von Willebrand’s disease. J Lab Clin Med 1983; 101: 411-425
• 7 Ginsburg D, Sadler JE. Von Willebrand disease: a database of point mutations, insertions, and deletions. Thromb Haemost 1993; 69: 177-184
• 8 Mancuso DJ, Tuley E, Westfield LA, Worrall NK, Shelton-Inloes BB, Sorace JM, Alevy YG, Sadler JE. Structure of the gene for human von Willebrand factor. J Biol Chem 1989; 264: 19514-1927
• 9 Gaucher C, Parquet-Gemez A, Hanss M, Horellou M-H, Goudemand M, Mazurier C. Potential new mutations in French families with type IIA and IIB von Willebrand’s disease. Proceedings of the XX International Congress of the World Federation of Hemophilia. 1992 347. (abstract)
• 10 Mazurier C, Parquet-Gemez A, Goudemand J, Taillefer MF, Goudemand M. Investigation of a large kindred with type IIB von Willebrand’s disease, dominant inheritance and age-dependent thrombocytopenia. Br J Haematol 1988; 69: 499-505
• 11 Mazurier C, Mannucci PM, Parquet-Gernez A, Goudemand M, Meyer D. Investigation of a case of subtype IIC von Willebrand disease: Characterization of the variability of this subtype. Amer J Hematol 1986; 22: 301-311
• 12 Gaucher C, Diéval J, Mazurier C. Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease. Blood 1994; 84: 1024-1030
• 13 Soulier J-P, Larrieu M-J. Nouvelle méthode de diagnostic de l’hémophilie. Dosage des facteurs antihémophiliques A et B Sang 1953; 24: 205-215
• 14 Girma J-P, Lavergne J-M, Meyer D, Larrieu M-J. Immunoradiometric assay of factor VIII: coagulant antigen using four human antibodies. Study of 27 cases of haemophilia A Br J Haematol 1981; 47: 269-282
• 15 Mazurier C, Parquet-Gernez A, Goudemand M. Dosage de l’antigène lié au facteur VIII par la technique ELISA. Intérêt dans l’étude de la maladie de Willebrand Path Biol 1977; 25: 18-24
• 16 Mc Farlane DE, Stribbe J, Kirby EP, Zucker MB, Grant RA, Mc Pherson JA. A method of assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 1975; 34: 306-308
• 17 Mazurier C, Samor B, Goudemand M. Improved characterization of plasma von Willebrand factor heterogeneity when using 2.5 % agarose gel electrophoresis. Thromb Haemost 1986; 55: 61-64
• 18 Meulien P, Nishino M, Mazurier C, Dott K, Piétu G, Jorieux S, Pavirani A, Girma J-P, Oufkir D, Courtney M, Meyer D. Processing and characterization of recombinant von Willebrand factor expressed in different cell types using a vaccinal virus vector. Thromb Haemost 1992; 67: 154-160
• 19 Randi AM, Rabinowitz I, Mancuso DJ, Mannucci PM, Sadler JE. Molecular basis of von Willebrand disease in type IIB. Candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein lb binding sequences J Clin Invest 1991; 87: 1220-1226
• 20 Eikenboom JC, Reitsma PH, Briët E. Seeming homozygosity in type IIB von Willebrand’s disease due to a polymorphism within the sequence of a commonly used primer. Ann Hematol 1994; 68: 139-141
• 21 Hilbert L, Gaucher C, de Romeuf C, Horellou M-H, Vink T, Mazurier C. Leu 697->Val mutation in mature von Willebrand factor is responsible for type IIB von Willebrand disease. Blood 1994; 83: 1542-1550
• 22 Kunkel GR, Graham JB, Fowlkes DM, Lord ST. AccI polymorphism in von Willebrand factor (F8vWF) at codon 516. Nucleic Acids Res 1991; 19: 1729
• 23 Kunkel GR, Graham JB, Fowlkes DM, Lord ST. Rsal polymorphism in von Willebrand factor (vWF) at codon 789. Nucleic Acids Res 1990; 18: 4961
• 24 Cacheris PM, Nichols WC, Ginsburg D. Molecular characterization of a unique von Willebrand disease variant. J Biol Chem 1991; 266: 13499-13502
• 25 Mazurier C, Jorieux S, de Romeuf C, Samor B, Goudemand M. In vitro evaluation of a very high purity, solvent/detergent-treated, von Willebrand factor concentrate. Vox Sang 1991; 61: 1-7
• 26 Burnouf-Radosevich M, Burnouf T. Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate. Vox Sang 1992; 62: 1-11
• 27 Kroner PA, Kluessendorf ML, Scott JP, Montgomery RR. Expressed full- length von Willebrand factor containing missense mutations linked to type IIB von Willebrand disease shows enhanced binding to platelets. Blood 1992; 79: 2048-2055
• 28 Cooney KA, Nichols WC, Bruck ME, Bahou WF, Shapiro AD, Bowie EJ, Gralnick HR, Ginsburg D. The molecular defect in type IIB von Willebrand disease. Identification of four potential missense mutations within the putative GPIb binding domain J Clin Invest 1991; 87: 1227-1233
• 29 Murray EW, Giles AR, Lillicrap D. Germ-line mosaicism for a Valine-to- Methionine substitution at residue 553 in the glycoprotein Ib-binding domain of von Willebrand factor causing type IIB von Willebrand disease. Am J Hum Genet 1992; 50: 199-207
• 30 Piétu G, Ribba A-S, de Paillette G, Chérel G, Lavergne J-M, Bahnak BR, Meyer D. Molecular study of von Willebrand disease : identification of potential mutations in patients with type IIA and IIB. Blood Coag Fibrinol 1992; 3: 415-421
• 31 Ribba AS, Christophe O, Derlon A, Cherel G, Siguret V, Lavergne JM, Girma JP, Meyer D, Piétu G. Discrepancy between IIA phenotype and IIB genotype in a patient with a variant of von Willebrand disease. Blood 1994; 83: 833-841
• 32 Bonthron D, Orr EC, Mitsock LM, Ginsburg D, Handin RI, Orkin SH. Nucleotide sequence of the pre-pro-von Willebrand factor cDNA. Nucleic Acids Res 1986; 14: 7125-7127